Table 1.
Characteristics of Patients in Group 1 with and without Normalization of Pulmonary Function and Patients in Group 2
| Characteristic | Group 1 (n = 188) | Normalization
|
P Value* | Group 2 (n = 120) | P Value† | |
|---|---|---|---|---|---|---|
| Yes (n = 51) | No (n = 137) | |||||
| Age, yr | .16 | .003 | ||||
| Mean (SD) age at HCT | 13.54 (3.49) | 12.90 (3.60) | 13.77 (3.44) | 12.28 (3.78) | ||
| Median | 13.82 | 13.45 | 13.91 | 12.50 | ||
| Range | 6.60–20.45 | 6.60–18.83 | 6.64–20.45 | 6.21–20.08 | ||
| Race, n (%) | .63 | .58 | ||||
| White | 136 (72) | 37 (72) | 99 (72) | 93 (78) | ||
| African-American | 35 (19) | 8 (16) | 27 (20) | 17 (14) | ||
| Other | 17 (9) | 6 (12) | 11 (8) | 10 (8) | ||
| Male sex, n (%) | 105 (56) | 25 (49) | 80 (58) | .32 | 67 (56) | 1.00 |
| Underlying disease, n (%) | .74 | .30 | ||||
| Hematologic malignancy | 152 (81) | 39 (76) | 113 (83) | 93 (77) | ||
| Heme disorders | 29 (15) | 10 (20) | 19 (14) | 24 (20) | ||
| Immune disorders | 3 (2) | 1 (2) | 2 (1) | 3 (3) | ||
| Solid tumors | 4 (2) | 1 (2) | 3 (2) | 0 (0) | ||
| Remission at HCT, n (%) | 120 (64) | 28 (55) | 92 (67) | .13 | 77 (64) | 1.00 |
| Donor match, n (%) | .23 | .30 | ||||
| Fully matched | 129 (69) | 40 (78) | 89 (65) | 92 (77) | ||
| Haploidentical | 44 (23) | 9 (18) | 35 (25) | 20 (17) | ||
| Mismatched | 15 (8) | 2 (4) | 13 (10) | 8 (6) | ||
| Multiple transplants, n (%) | 39 (21) | 6 (12) | 33 (24) | .07 | 6 (5) | .39 |
| Product type, n (%) | .04 | .004 | ||||
| HPC-A | 55 (29) | 11 (21) | 44 (32) | 17 (14) | ||
| HPC-M | 131 (70) | 38 (75) | 93 (68) | 102 (85) | ||
| HPC-C | 2 (1) | 2 (4) | 0 (0) | 1 (1) | ||
| Time cohort, n (%) | .29 | .90 | ||||
| Before 2000 | 54 (29) | 18 (35) | 36 (26) | 36 (30) | ||
| On or after 2000 | 134 (71) | 33 (65) | 101 (74) | 84 (70) | ||
| T cell depletion, n (%) | 66 (35) | 15 (29) | 51 (37) | .39 | 35 (29) | .32 |
| Reduced-intensity conditioning, n (%) | 50 (27) | 11 (22) | 39 (29) | .45 | 36 (30) | .52 |
HPC-M indicates human progenitor cell, marrow; HPC-A, human progenitor cell, apheresis or peripheral blood stem cell product; HPC-C, human progenitor cell, cord.
Group 1 includes patients with 3 or more PFT results, of which at least 1 was abnormal. Group 2 includes patients with 3 or more PFT results, all of which were normal.
*
P value comparing patients in group 1 who did and did not normalize lung function.
†
P value comparing patients in group 1 and group 2.